HR Execs on the Move

Leiters

www.leiters.com

 
Leiters is a FDA-registered 503B outsourcing provider of high quality ophthalmology and hospital-based services. We are committed to providing healthcare professionals and their patients with high quality medications.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.leiters.com
  • 17 Great Oaks Blvd
    San Jose, CA USA 95119
  • Phone: 800.292.6772

Executives

Name Title Contact Details
Carie Edquist
Vice President Finance Profile
Violet Dhawan
Chief Financial Officer Profile

Similar Companies

Abner Labs

Abner Innovation Laboratories Limited (“Abner Labs”) is a British Columbia, Canada, company formed to acquire Abner Technology Group Limited (“Abner Group”), owner of the ibetmobile sports viewing and betting technology platform. This proprietary, artificial intelligence (“AI”) driven smart technology makes watching and wagering on live sports on any online device as easy as playing video games.

Synthonics

Synthonics is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cedarburg Hauser Pharmaceuticals

Cedarburg Pharmaceuticals delivers unsurpassed value in the development and manufacturing of commercial and clinical APIs. We believe value is more than just price. Value means making your life simpler. Our process development, scale-up, commercial

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.

Armstrong Pharmaceuticals Inc

Armstrong Pharmaceuticals, Inc. was founded in 1955 as a manufacturer of specialty aerosol products. Armstrong produced a wide array of topical, personal care, and pharmaceutical products. Since 1993, Armstrong has focused exclusively on pharmaceutical